Ramsay M E, Andrews N, Kaczmarski E B, Miller E
Lancet. 2001 Jan 20;357(9251):195-6. doi: 10.1016/S0140-6736(00)03594-7.
The UK was the first country to use meningococcal serogroup C conjugate (MCC) vaccines, which were licensed on the basis of immunogenicity and safety data but without a formal efficacy study. Increased surveillance during the first 9 months since introduction has shown that short-term efficacy of the MCC vaccine in England was 97% (95% CI 77-99) for teenagers and 92% (65-98) for toddlers. These early results confirm the superiority of MCC over plain C polysaccharide vaccines, which are ineffective in young children.
英国是首个使用脑膜炎球菌C群结合疫苗（MCC）的国家，该疫苗是根据免疫原性和安全性数据获批上市的，但未经过正式的效力研究。自引入该疫苗后的前9个月里加强监测显示，MCC疫苗在英格兰对青少年的短期效力为97%（95%可信区间77-99），对幼儿为92%（65-98）。这些早期结果证实了MCC相对于普通C多糖疫苗的优越性，普通C多糖疫苗对幼儿无效。
